S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Dyadic International Stock Forecast, Price & News

-0.01 (-0.33%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
1,773 shs
Average Volume
26,933 shs
Market Capitalization
$85.91 million
P/E Ratio
Dividend Yield
Price Target

Dyadic International MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
97.4% Upside
$6.00 Price Target
Short Interest
2.08% of Float Sold Short
Dividend Strength
News Sentiment
1.87mentions of Dyadic International in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.23) to $0.03 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.99 out of 5 stars

Medical Sector

638th out of 1,428 stocks

Biological Products, Except Diagnostic Industry

104th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive DYAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter.

Dyadic International logo

About Dyadic International (NASDAQ:DYAI) Stock

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

DYAI Stock News Headlines

Dyadic International, Inc. (DYAI)
DYAI: 2021 Results
Dyadic International earnings preview: what Wall Street is expecting
A Preview Of Dyadic International's Earnings
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$2.40 million
Book Value
$0.65 per share


Free Float
Market Cap
$85.91 million
Not Optionable

Dyadic International Frequently Asked Questions

Should I buy or sell Dyadic International stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dyadic International stock.
View analyst ratings for Dyadic International
or view top-rated stocks.

What is Dyadic International's stock price forecast for 2022?

1 analysts have issued 1 year price targets for Dyadic International's shares. Their DYAI stock forecasts range from $6.00 to $6.00. On average, they predict Dyadic International's share price to reach $6.00 in the next year. This suggests a possible upside of 97.4% from the stock's current price.
View analysts' price targets for Dyadic International
or view top-rated stocks among Wall Street analysts.

How has Dyadic International's stock price performed in 2022?

Dyadic International's stock was trading at $4.52 on January 1st, 2022. Since then, DYAI shares have decreased by 32.7% and is now trading at $3.04.
View the best growth stocks for 2022 here

When is Dyadic International's next earnings date?

Dyadic International is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Dyadic International

How were Dyadic International's earnings last quarter?

Dyadic International, Inc. (NASDAQ:DYAI) announced its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts' consensus estimates of ($0.09). The biotechnology company earned $0.65 million during the quarter, compared to analyst estimates of $2.37 million. Dyadic International had a negative trailing twelve-month return on equity of 61.46% and a negative net margin of 473.45%.
View Dyadic International's earnings history

Who are Dyadic International's key executives?

Dyadic International's management team includes the following people:

What other stocks do shareholders of Dyadic International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Ampio Pharmaceuticals (AMPE), Alibaba Group (BABA) and Chimerix (CMRX).

What is Dyadic International's stock symbol?

Dyadic International trades on the NASDAQ under the ticker symbol "DYAI."

How do I buy shares of Dyadic International?

Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dyadic International's stock price today?

One share of DYAI stock can currently be purchased for approximately $3.04.

How much money does Dyadic International make?

Dyadic International (NASDAQ:DYAI) has a market capitalization of $85.91 million and generates $2.40 million in revenue each year. The biotechnology company earns $-13,070,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

How many employees does Dyadic International have?

Dyadic International employs 7 workers across the globe.

How can I contact Dyadic International?

Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The official website for Dyadic International is www.dyadic.com. The biotechnology company can be reached via phone at (561) 743-8333, via email at prawson@dyadic.com, or via fax at 561-743-8343.

This page (NASDAQ:DYAI) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.